Person:
FİLİNTE, DENİZ

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

FİLİNTE

First Name

DENİZ

Name

Filters

2020 - 20223
Reset filters

Settings

Author: ÇAM, HAYDAR KAMİL ×

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    PublicationMetadata only
    Is Cognitive MR Fusion Biopsy Superior to Standard TRUS Guided Prostate Biopsy? Our Clinical Experience
    (2022-06-01) FİLİNTE, DENİZ; ÇAM, HAYDAR KAMİL; ŞAHİN, BAHADIR; DÖRÜCÜ, DOĞANCAN; ŞAHİN B., DÖRÜCÜ D., TİNAY İ., FİLİNTE D., ÇAM H. K.
    Objective: To share our clinical experience with cognitive prostate biopsy and compare results of cognitive biopsies with standard biopsies.
  • Thumbnail Image
    PublicationOpen Access
    Atypical Cell'' Parameter in Automated Urine Analysis for the Diagnosis of Bladder Cancer: A Retrospective Pilot Study
    (GALENOS YAYINCILIK, 2020-04-01) FİLİNTE, DENİZ; Tinay, Ilker; Sahin, Bahadir; Saracoglu, Sertac; Yanilmaz, Ozgur; Aksu, Mehmet Burak; Ayas, Ramazan; Filinte, Deniz; Cam, Haydar Kamil; Ilki, Arzu
    Objective: To evaluate the application of an automated urine analyzer (AUA) for the diagnosis of bladder cancer (BC) Materials and Methods: A retrospective data analysis of 2365 urine specimens from the department of urology has been performed and matched with those patients, who have undergone cystoscopic evaluation or surgical treatment for different urological pathologies during 2018. After matching, clinical records of the patients has been further evaluated in order to select patients with recent or previous BC diagnosis. To assess the diagnostic efficacy of AUA, patients were divided into five groups according to the patient history of BC and healthy controls. Results: A total of 106 patients are included in this study and the majority (69.8%) of the patients are follow-up patients with previous diagnosis and treatment of non-muscle invasive BC (NMIBC). For patients with low-risk NMIBC (n=27), the sensitivity and specificity were calculated as 75% and 100%. For patients with high-risk NMIBC (n=47), who were previously treated with intravesical BCG, the sensitivity and specificity were calculated as 54.5% and 83.3%. All patients in radical cystectomy group (n=7) with muscle invasive BC had positive urine analyses results for atypical cells. And none of the patients in the control group (n=8) had positive AUA results and cystoscopic evaluation also did not show any bladder mass suspicious for BC. Conclusion: The results of this retrospective pilot study showed acceptable sensitivity and specificity rates of the fluorescence flow cytometry based AUA and the results of the low-risk group are especially valuable regarding its potential use to decide on performing a follow-up cystoscopy or not. A prospective study is currently on progress to validate the findings of the current study.
  • Thumbnail Image
    PublicationOpen Access
    Risk factors of patients with prostate cancer upgrading for international society of urological pathology grade group I after radical prostatectomy
    (2022-01-01) ÖZGÜR, GÜNAL; FİLİNTE, DENİZ; ÇAM, HAYDAR KAMİL; ÖZGÜR A., ÖZGÜR G., ŞAHİN B., FİLİNTE D., TİNAY İ., ÇAM H. K., TÜRKERİ N. L.
    Objective: This study aimed to determine the predictive factors for patients whose International Society of Urological Pathology (ISUP) score was upgraded in radical prostatectomy (RP) pathologies with a prostate biopsy pathology of ISUP grade group 1. Materials and Methods: Among patients who underwent RP in our clinic within 10 years, 158 patients with prostate biopsy pathology of ISUP grade group 1 were examined retrospectively. Age, serum prostate-specific antigen (PSA) level, prostate biopsy ISUP grade group, number of cores taken in the prostate biopsy, number of tumor-positive cores, RP pathology ISUP grade group, and pathological stage were evaluated. Results: The mean age (± standard) of the 158 patients whose prostate biopsy pathology was ISUP grade group 1 were 64.07 (±6.6). ISUP group upgrading was detected in 47 patients (29.7%). The mean PSA value of these patients was 10.6 ng/mL (±6.9). The mean PSA value of the other 111 patients without ISUP group upgrading was 7.98 ng/mL (±4.9). The serum PSA level was significantly higher in patients with upgraded ISUP in the RP pathology (p=0.02). The percentage of tumor-positive cores in the group with ISUP group upgrading (37%) was significantly higher than that in the group without ISUP group upgrading (27%) (p=0.01). The detection rates of surgical margin positivity (42.6% vs. 18%), capsule invasion (55.3% vs. 19.8%), and seminal vesicle invasion (23.6% vs. 3.6%) were also significantly higher in the upgraded ISUP group after RP (p<0.05). Conclusion: The results of this trial suggest that active surveillance may not be an appropriate option for patients with biopsy ISUP grade group 1 with PSA level >10 ng/mL. Moreover, the presence of a higher number and percentage of tumor-positive cores constituted risks of ISUP group upgrading with concomitant poor pathological outcomes such as surgical margin positivity, capsule invasion, and seminal vesicle invasion.